Phase I/II Clinical Trials Prostate Cancer

A Phase I/II clinical trial (SP015) was launched in 2018 to test the effects of the combination of DCVAC/PCa and ONCOS-102, which is targeted at prostate cancer patients. This clinical trial is currently being conducted at the Urology Clinic of the University Hospital in Motol, Prague.

Description of Phase I/II Clinical Trial (DCVAC/PCa)

Clinical Trial SP015 (Eudra CT: 2015-004314-15) is a Phase I/II, single-arm clinical trial to evaluate the safety and immune activation of the combination of DCVAC/PCa, an active cellular immunotherapy, and ONCOS-102, an immune-priming adenovirus, in men with advanced metastatic castration-resistant prostate cancer. This clinical trial has started in May 2018. The planned number of patients enrolled is up to 15. For more information visit .

Only a physician conducting a clinical evaluation of an investigational treatment SOTIO® DCVAC/PCa can include a patient in a clinical trial. If a patient with prostate cancer would like to participate in a trial he can contact participating medical center.

List of participating Medical Centers
Medical Center Address Department Clinical Trial Number
Fakultní nemocnice v Motole V Úvalu 84
Praha 5
150 06
Czech Republic
Urology Clinic of Charles University's Second Faculty of Medicine and Motol University Hospital SP015